Sugi Predict

Sugi Predict / Targets / CYP2C18

CYP2C18

Cytochrome P450 2C18 · P33260 · CYP2C18 on Sugi Atlas →

8,238 patent compounds predicted against CYP2C18, 5,228 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL896130 SCHEMBL896130 1.00 13/20
Sulfaphenazole Sulfaphenazole (SCHEMBL122040) 1.00 7/20
SCHEMBL1906019 SCHEMBL1906019 0.40 5/20
SCHEMBL1846495 SCHEMBL1846495 0.47 4/20
SCHEMBL433371 SCHEMBL433371 0.45 4/20
SCHEMBL2003516 SCHEMBL2003516 0.48 3/20
SCHEMBL1165314 SCHEMBL1165314 0.47 3/20
SCHEMBL2511848 SCHEMBL2511848 0.44 3/20
SCHEMBL411379 SCHEMBL411379 0.44 3/20
SCHEMBL971260 SCHEMBL971260 0.42 3/20
SCHEMBL2091704 SCHEMBL2091704 0.41 3/20
SCHEMBL971261 SCHEMBL971261 0.40 3/20
SCHEMBL1779238 SCHEMBL1779238 0.39 3/20
SCHEMBL519029 SCHEMBL519029 0.36 3/20
Trifluoroacetic Acid Trifluoroacetic Acid (SCHEMBL2566375) 0.90 2/20
Trifluoroacetic Acid Trifluoroacetic Acid (SCHEMBL2570005) 0.89 2/20
SCHEMBL2407878 SCHEMBL2407878 0.74 2/20
SCHEMBL196765 SCHEMBL196765 0.73 2/20
SCHEMBL1180429 SCHEMBL1180429 0.67 2/20
SCHEMBL1181635 SCHEMBL1181635 0.67 2/20

Clinical trials — most relevant to CYP2C18 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Efficacy and Safety of 3D185 Monotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Cholangiocarcinoma PHASE2NOT_YET_RECRUITING
Study to Evaluate the Safety and Efficacy of SPR001 in Subjects With Classic Congenital Adrenal Hyperplasia PHASE2COMPLETED
A Trial of Androgen Deprivation, Docetaxel, and Enzalutamide for Metastatic Prostate Cancer PHASE2ACTIVE_NOT_RECRUITING
Determine Function of Antroquinonol in Combination With SOC in First Line Metastatic Pancreatic Cancer PHASE1/PHASE2ACTIVE_NOT_RECRUITING
Tovorafenib for Treatment of Craniopharyngioma in Children and Young Adults PHASE2RECRUITING
Long Term Safety and Efficacy Study of Tolebrutinib (SAR442168) in Participants With Relapsing Multiple Sclerosis PHASE2COMPLETED
Double-blind Study to Evaluate the Safety and Efficacy of Antroquinonol in Mild-Moderate COVID-19 Hospitalized Patients PHASE2COMPLETED
A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation. PHASE2RECRUITING
Befotertinib and Icotinib in Treatment-naive Patients With Advanced EGFR-Mutant Lung Cancer PHASE2ACTIVE_NOT_RECRUITING
Study of Tucatinib and Doxil in Participants With Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer PHASE2RECRUITING
Treatment With Tucatinib in Patients With an Isolated Brain Progression of a Metastatic Breast Cancer PHASE2ACTIVE_NOT_RECRUITING
A Phase 2 Study of the MET Kinase Inhibitor INC280 in Papillary Renal Cell Cancer PHASE2COMPLETED
Repeat Dose Safety and Efficacy Study for Compound to Treat Anemia PHASE2COMPLETED
Intermittent Dosing Of Selumetinib In Childhood NF1 Associated Tumours PHASE1/PHASE2COMPLETED
Irinotecan Liposome II + 5-FU/LV + Oxaliplatin + Karelizumab in Neoadjuvant Treatment of Gastric Cancer PHASE2NOT_YET_RECRUITING
Phase 2 Study of INV-202 in Patients With Diabetic Kidney Disease PHASE2COMPLETED
Open-Label Study to Determine the Maximum Tolerated Oral Dose of the Kinase Inhibitor CEP-11981 in Patients With Advanced Cancer PHASE1COMPLETED
A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AG-181 in Subjects With Phenylketonuria PHASE1RECRUITING
A Study of HSK29116 in Adults With Relapsed/Refractory B-cell Malignancies PHASE1UNKNOWN
Study of FCN-098 in Patients With Advanced Solid Tumor PHASE1UNKNOWN
Cocktail Approach for Cytochrome P450 and P-glycoprotein Activity Assessment Using Dried Blood Spot PHASE1COMPLETED
Study of SHR6390 in Renal Insufficiency and Healthy Subjects PHASE1UNKNOWN
Phase 1 Dose Escalation Study of CGX1321 in Subjects With Advanced Gastrointestinal Tumors PHASE1UNKNOWN
Study of the Safety and Effectiveness of LGH447 and BYL719 in Patients With Relapsed and Refractory Multiple Myeloma PHASE1COMPLETED
A Study to Evaluate the Effect of Genotype on LY2216684 PHASE1COMPLETED
Pilot LDE225 in Locally Advanced or Metastatic BCC + Previously Tx Non-LDE225 Smoothened Inhibitors nanCOMPLETED
CYP2C19 Variants and Limonene Metabolism nanRECRUITING
Pilot Study to Determine Pro-Inflammatory Cytokine Kinetics During Immune Checkpoint Inhibitor Therapy nanCOMPLETED
Pharmacogenomic Profiling of Pediatric Patients nanCOMPLETED
Genetic Study of Liver Enzymes in Patients With Side Effects From Antidepressants nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a CYP2C18 binder may also engage these)

ProteinNameSimilarity
P15123 — 1.000 P15123 →
P33264 — 1.000 P33264 →
CYP2C19 Cytochrome P450 2C19 1.000 landscape →
P33263 — 0.999 P33263 →
Q08078 — 0.998 Q08078 →
P00180 — 0.997 P00180 →
P17666 — 0.997 P17666 →
P56656 — 0.997 P56656 →
CYP2C8 Cytochrome P450 2C8 0.996 landscape →
P00179 — 0.996 P00179 →
P33265 — 0.995 P33265 →
P00181 — 0.995 P00181 →
Q64458 — 0.994 Q64458 →
P08683 — 0.993 P08683 →
P33262 — 0.993 P33262 →
P20812 — 0.993 P20812 →
CYP2A7 Cytochrome P450 2A7 (EC 1.14.14.1) (CYPIIA7) 0.993 landscape →
P33273 — 0.992 P33273 →
P05179 — 0.992 P05179 →
P11371 — 0.992 P11371 →
CYP2A13 Cytochrome P450 2A13 0.991 landscape →
P10610 — 0.990 P10610 →
P56654 — 0.990 P56654 →
P11372 — 0.990 P11372 →
Q64583 — 0.990 Q64583 →
O55071 — 0.990 O55071 →
P33272 — 0.989 P33272 →
P20852 — 0.988 P20852 →
CYP2C9 Cytochrome P450 2C9 0.988 landscape →
P56655 — 0.988 P56655 →